Department of Vascular Surgery, The Second Hospital of Yinzhou District, Ningbo, Zhejiang Province, People's Republic of China.
Department of Orthopedic Surgery, The Second Hospital of Yinzhou District, Ningbo, Zhejiang Province, People's Republic of China.
Kaohsiung J Med Sci. 2023 Jun;39(6):596-604. doi: 10.1002/kjm2.12663. Epub 2023 Mar 13.
Tanshinone IIA (Tan IIA) has an important role in treatment of cardiovascular diseases, including atherosclerosis. The vascular smooth muscle cells (VSMCs) are a major part of the atherosclerotic plaque. However, the biological functions of Tan IIA in regulating VSMCs function remain mostly unclear. This research aimed at identifying the explicit molecular mechanism that Tan IIA regulates oxidized low-density lipoprotein (ox-LDL)-mediated VSMC proliferation and migration. VSMCs challenged by ox-LDL were adopted as cellular model of atherosclerosis, and suffered from Tan IIA treatment. After that, cells proliferation, apoptosis or migration were measured. The expression levels of microRNA (miR)-137, transient receptor potential cation channel subfamily C member 3 (TRPC3) and proliferating cell nuclear antigen (PCNA) were measured. The targeting relationship between miR-137 and TRPC3 was determined. It was found that Tan IIA blunted VSMC proliferation, PCNA expression and migration mediated by ox-LDL. Tan IIA promoted miR-137 level, and miR-137 knockdown reversed the influences of Tan IIA on VSMC proliferation, PCNA expression and migration in the presence of ox-LDL. TRPC3 was verified to be targeted by miR-137. Moreover, TRPC3 silencing exacerbated the influences of Tan IIA on VSMC proliferation, apoptosis and migration, and it mitigated the inhibitive effects of miR-137 knockdown on function of Tan IIA. We confirmed for the first time that Tan IIA constrained ox-LDL-stimulated VSMC proliferation and migration via regulating the miR-137/TRPC3 axis, which provided a theoretical basis for the research and promotion of Tan IIA as a therapeutic drug.
丹参酮 IIA(Tan IIA)在治疗心血管疾病,包括动脉粥样硬化方面起着重要作用。血管平滑肌细胞(VSMCs)是动脉粥样硬化斑块的主要组成部分。然而,Tan IIA 调节 VSMC 功能的生物学功能在很大程度上仍不清楚。本研究旨在确定 Tan IIA 调节氧化型低密度脂蛋白(ox-LDL)介导的 VSMC 增殖和迁移的确切分子机制。采用 ox-LDL 刺激的 VSMC 作为动脉粥样硬化的细胞模型,并进行 Tan IIA 处理。然后,测量细胞增殖、凋亡或迁移。测量微小 RNA(miR)-137、瞬时受体电位阳离子通道亚家族 C 成员 3(TRPC3)和增殖细胞核抗原(PCNA)的表达水平。确定 miR-137 和 TRPC3 之间的靶向关系。结果发现,Tan IIA 减弱了 ox-LDL 介导的 VSMC 增殖、PCNA 表达和迁移。Tan IIA 促进了 miR-137 的水平,并且 miR-137 的敲低逆转了 Tan IIA 在 ox-LDL 存在下对 VSMC 增殖、PCNA 表达和迁移的影响。TRPC3 被验证为 miR-137 的靶标。此外,TRPC3 沉默加剧了 Tan IIA 对 VSMC 增殖、凋亡和迁移的影响,并减轻了 miR-137 敲低对 Tan IIA 功能的抑制作用。我们首次证实,Tan IIA 通过调节 miR-137/TRPC3 轴来限制 ox-LDL 刺激的 VSMC 增殖和迁移,为 Tan IIA 作为治疗药物的研究和推广提供了理论依据。